Vidofludimus Calcium Demonstrates Therapeutic Potential in Latest Phase 2 CALLIPER Trial Data of Progressive Multiple Sclerosis

Vidofludimus calcium lowers risk of progressive MS disability...

Vidofludimus calcium, an experimental oral therapy from Immunic Therapeutics, reduced the risk of confirmed disability worsening and slowed brain shrinkage in people with progressive forms of multiple sclerosis (MS). That’s […] The post Vidofludimus calcium lowers risk of progressive MS disability worsening appeared first on Multiple Sclerosis News Today.

Rimming for rapid worsening. Is it a cucumber slice?

MRI has revolutionised detection and monitoring of brain disease but it has to be said many of the imaging modalities used in research and trials have never made it into clinical practise. Gadolini…

Vidofludimus Calcium Demonstrates Therapeutic Potential in Latest Phase 2 CALLIPER Trial Data of Progressive Multiple Sclerosis

Overall, Vidofludimus calcium demonstrated a 20% reduction in confirmed disability worsening events and modest benefits on brain volume change in patients with progressive multiple sclerosis.

Immunic unveils positive data from Phase 2 trial of IMU-838 in progressive MS - BioTuesdays

Immunic (NASDAQ:IMUX) announced positive Phase 2 CALLIPER data demonstrating its nuclear receptor related 1 (Nurr1) activator—vidofludimus calcium (IMU-838)—reduced the risk of progressive multiple sclerosis (PMS) worsening by 30%. According to Immunic, reduction of confirmed disability worsening is widely considered to be the most recognized regulatory approval endpoint for registrational studies in progressive forms MS. In a statement, Daniel …